Multiple later-stage clinical trial programs are under way in Alzheimer’s disease, including several for therapies that target amyloid. Among the potential Aduhelm competitors:

Roche Holding AG has completed enrollment in its Phase III GRADUATE-1 and GRADUATE-2 studies of the amyloid-targeting antibody gantenerumab with about 1,000 patients each trial and results expected in 2022. (Also see "Roche Confident But Cautious On Alzheimer's Hopeful" - Scrip, 8 February, 2021.)
Lilly initiated TRAILBLAZER-ALZ 2 as a 500-plus-patient Phase IIb trial a year ago but increased the study to 1,500 patients and converted it to a Phase III trial in March. (Also see "Lilly’s New Anti-Amyloid Play Hinges On Tau Bet" - Scrip, 16 March, 2021.)
Alzheon Inc. is recruiting 300 patients with early Alzheimer’s disease and the APOE4/4 genotype for the Phase III APOLLOE4 study of ALZ-801, a prodrug of tramiprosate, which interferes with the association between glycosaminoglycans and amyloid beta. (Also see "Alzheon IPO To Fund New Phase III Trialling Of Failed Alzheimer's Drug " - Scrip, 19 March, 2018.)
AZTherapies, Inc. said in November that it completed the Phase III COGNITE trial that tested ALZT-OP1 in more than 600 patients and planned to report the results in the first quarter of 2021. The drug is designed to inhibit beta-amyloid peptide polymerization and the neuro-inflammatory response. (Also see "Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery" - Scrip, 2 October, 2020.)
Biogen and Eisai are testing lecanemab (BAN2401), which targets amyloid protofibrils, in the fully enrolled 1,795-patient Phase III Clarity AD trial and the Phase III AHEAD 3-45 study, which will enroll 1,400 patients. (Also see "Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s" - Scrip, 14 July, 2020.)

Free Access To High-Cost Aducanumab May Incentivize Phase IV Trial Participants

Accelerated Approval Adds Another Alzheimer’s Study To Global Pipeline

More from Clinical Trials

More from R&D